Financials
Financial year 2025
Worth noting
- Little cash and receivables against the short-term debts.
Revenue
€ 23.8 million
▼ 12% vs 2024
Profit
Healthy€ 984,307
▼ 2% vs 2024
Debts
Low€ 6 million
▼ 22% vs 2024
INTERNATIONAL MEDICAL PRODUCTS from Sint-Gillis (bij-Brussel), company number BE0426041123, closed financial year 2025 with a result of € 984,307 after tax. For that financial year INTERNATIONAL MEDICAL PRODUCTS recorded revenue of € 23.8 million and equity of € 4.2 million. Compared with financial year 2024, the result moved from € 1 million to € 984,307. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
What happened at INTERNATIONAL MEDICAL PRODUCTS?
What happened at INTERNATIONAL MEDICAL PRODUCTS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- JESSICA WEVE stepped down as director. NBB
- NATALIS DEVELOPPEMENT SAS stepped down as director. NBB
- MB SOLUTIONS SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 984,307 (▼ 2% vs 2024). Source: NBB ↗
- NATALIS DEVELOPPEMENT SAS became a director. NBB
- JESSICA WEVE became a director. NBB
- MB SOLUTIONS SRL became a director. NBB
- New establishment in Sint-Gillis (bij-Brussel). KBO
In short
From € 68,713 loss in 2021 to € 984,307 profit in 2025.
Paid € 30,698 in corporate taxes since 2021.
Best year ever: 2023, with € 1.1 million profit.
Pays suppliers within 39 days on average.
A new publication or filing at INTERNATIONAL MEDICAL PRODUCTS? We notify you, reason included.
Follow INTERNATIONAL MEDICAL PRODUCTSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by MEDIPREMA GROUP (100%). It owns 100% of BELDICO BV, 54% of BELDICO SA and 50% of BELDICO FRANCE SAS itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
Managing director · represented by Vincent Camus
since 2026 · until 2031
Director · represented by MARC BEMELMANS
Also active at: BELGIAN DIAGNOSTIC COMPANY
since 2025 · until 2031
Shareholders
MEDIPREMA GROUP
100%
Participations
Establishments
Establishment units
Physical locations of this company
Marcel Broodthaersplein 8 box 5
1060 Sint-Gillis (bij-Brussel)
Aye, Rue André Feher 5
6900 Marche-en-Famenne
Active since 22 April 2002
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 83 companies are registered at this address.
Thalie
€ 2 million gross margin · 2026
DIENST VOOR TOERISME DER SPOORMANNEN - OFFICE DE TOURISME DES CHEMINOTS
Elbi
€ 1.5 million gross margin · 2026
REICO
€ 3,653 revenue · 2025
SOCIETE GABRIELLE
€ 388,904 gross margin · 2026
+78 more
Details
- Company number
- 0426.041.123
- VAT number
- BE 0426.041.123
- Registered office
- Marcel Broodthaersplein 8 bus 5, 1060 Sint-Gillis (bij-Brussel)
- Names & denominations
- INTERNATIONAL MEDICAL PRODUCTS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 August 1984
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels